Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thrasos Therapeutics Inc.

Latest From Thrasos Therapeutics Inc.

Venture Funding Deals, May 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2015.

BioPharmaceutical Medical Device

Deals Of The Week: Shire/arGEN-X/Ethris, Evotec/Yale, Amgen/Bind Biosciences

GSK’s venture arm outlines its investment priorities, which involve changes to the biopharma business model.

BioPharmaceutical Deals

Recent Financings of Private Companies, November 2012

START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.

BioPharmaceutical Medical Device

Thrasos Therapeutics Inc.

Bone morphogenetic proteins interact with a number of related but structurally distinct BMP receptors, each with different biological effects, and researchers have eyed BMP for a number of therapeutic indications. But the proteins come with a big caveat: they tend to promote inappropriate bone growth at sites of infection and the spot where injected, and that side effect has derailed many therapeutic efforts. Thrasos Therapeutics Inc. aims to get around that problem by designing agonists that selectively activate the BMP-7 receptors that promote tissue growth and protection, without affecting those receptors that cause bone growth. Its lead programs include compounds designed to prevent and treat acute kidney injury and chronic kidney disease.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Thrasos Therapeutics Inc.
  • Senior Management
  • Jerome Rossert, MD, PhD, CSO & CMO
  • Contact Info
  • Thrasos Therapeutics Inc.
    Phone: (450) 682-5140
    7171 Frederick Banting
    NeoMed Ste 1228
    Montreal, MA H4S 1Z9